

**ASGCT Career Development Award**

**Overview and Benefits**

ASGCT will award a $50,000 Career Development Award for each of the broad topics listed below (6 total grants). The purpose of these awards is to support independent transformative pilot studies in gene and cell therapy by ASGCT members, particularly those ideas that would be challenging to fund with normal funding mechanisms. ASGCT is interested in helping applicants generate their own independent preliminary data to use in larger proposals (NIH K awards, first-submission R-level funding, etc.) to gain independence. Please select one of the topics below that best fits your proposal.

**A. Viral Vector Development.**

Includes any viral vector (RNA or DNA virus), and includes regulation of gene expression.

**B. Gene Targeting and Gene Correction.**

Basic development of novel technologies for genome editing, with or without nucleases. Gene targeting projects focused solely on specific disease applications should submit applications to the Clinical Translation of Gene and Cell Therapies category.

**C. Oligonucleotide Therapeutics.**

Includes siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, splice switching oligos, and plasmids*.*

**D. Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics.**

Includes any non-viral gene therapeutics delivery method, such as polymers, liposomes, exosomes, electroporation and other non-viral delivery methodologies.

**E. Immunological Aspects of Gene Therapy and Vaccines.**

Includes host responses and therapy/prevention of infectious diseases. Excludes cancer immunotherapy and cancer vaccines.

**F. Cell Therapies.**

Includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing. Includes cell-based strategies for cancer immunotherapy or similar.

**Eligibility Requirements**

Any ASGCT member type may apply who is in good standing or have a membership application pending. To verify your membership status, please [log in to your ASGCT account](https://asgct.execinc.com/edibo/Login/Default/call). **Not an ASGCT member yet?** [Take the first step](https://www.asgct.org/membership). Submit your membership application at least 5 business days prior to the application deadline to allow sufficient time for processing. The mentor is not required to be an ASGCT member. U.S. citizenship is not required but both the applicant and mentor must be located in the United States during the duration of the research. Any visa and/or citizenship restrictions applicable to receiving the award are the responsibility of the applicant.

**Application Process**

The ASGCT Career Development Award application documents outlined below must be submitted in **one combined PDF** to awards@asgct.org with the subject line **Last Name, First Name – 2019 CDA Application***.* Submissions after the deadline of August 1st at 11:59 pm (CST) will not be considered. The applicant will receive an email confirmation within 24 business hours to verify receipt of application.

**All applications must include the following and be submitted in a one combined PDF:**

1. Cover Page (limit 1 page and use the ASGCT required template)
2. Applicant Career Development Plan (limit 1 page)
3. Project Narrative (limit 2 pages)
4. Budget (limit 1 page)
5. Mentor Letter of Support (limit 2 pages)
6. Applicant NIH Biographical Sketch, CV/resume, or equivalent (limit 5 pages)
7. Mentor NIH Biographical Sketch, CV/resume, or equivalent (limit 5 pages)

For more details about the required materials, please see the [**Required Documents** **Checklist**](ASGCT%20Career%20Development%20Award%20%20-%202019%20Required%20Documents.pdf).

**Key Dates & Deadlines**

|  |  |
| --- | --- |
| Application Deadline | August 1, 2019 *by 11:59 pm CST* |
| Award Notification | October 2019 |
| Award Activation | November 2019 |
| Final Report Due | December 18, 2020 |
| Possible Presentation at the ASGCT 24th Annual Meeting in Portland, OR | May 10-15, 2021 |

**Evaluation and Selection**

Applications will be reviewed by an anonymous ASGCT member committee and will be evaluated on the following criteria:

* Significance, innovation, and originality of the proposed project.
* Appropriateness, feasibility, and adequacy of proposed project within the award timeline.
* Focus on basic, translational, or clinical health science of gene and cell therapy.
* Applicant's qualifications and experience, including potential for future independent career and a commitment to a career in gene and cell therapy.
* Applicant’s project proposal is innovative and transformative.
* Justification as to what the project results will bring to the field.

**Terms and Conditions**

As a condition of acceptance of the Career Development Award, it is required that:

* All funds must be used for direct expenses associated with conducting the proposed project, and are non-transferable. [Please refer to our Grant Policy Statement for a list of accepted costs.](Grants%20Policy%20Statement%202019.pdf)
* U.S. citizenship is not required but both the applicant and mentor must be located in the United States during the duration of the research.
* The recipient must submit a final report and budget by the deadline.
* The recipient may be asked to present at the ASGCT Annual Meeting in the year following the award activation. Travel may be reimbursed for this invited talk according to the ASGCT reimbursement policy.
* The recipient may be asked to provide updated career and employment information so that ASGCT can track the recipient’s progress following his/her award period, to maintain the ASGC7T webpage regarding past winners.
* Any unused funds must be returned to ASGCT.
* The recipient must cite support from ASGCT in any publication (pre-prints, peer-reviewed manuscripts, public talks/posters, etc.) describing research conducted during the award period. When publishing, the following phrase must be included in the acknowledgements:

*"The project described was supported by a Career Development Award from the American Society of Gene & Cell Therapy. The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Society of Gene & Cell Therapy."*

 **Questions:** please emailawards@asgct.org